Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

NCT00946023 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

135

Enrollment

OTHER

Sponsor class

Stopped Funding was unavailable to complete the study as originally planned.

Conditions

Lymphoma
B-cell Lymphoma
Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
RADIATION: Total body irradiation
DRUG: Tacrolimus
DRUG: Mycophenolate Mofetil
DRUG: Rituximab
BIOLOGICAL: Allogeneic Bone Marrow Transplant (BMT)

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins